These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18990168)

  • 1. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
    James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Anderson J; Popert RJ; Sanders K; Morgan RC; Stansfeld J; Dwyer J; Masters J; Parmar MK
    BJU Int; 2009 Feb; 103(4):464-9. PubMed ID: 18990168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
    James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Spears MR; Ritchie AW; Parker CC; Russell JM; Attard G; de Bono J; Cross W; Jones RJ; Thalmann G; Amos C; Matheson D; Millman R; Alzouebi M; Beesley S; Birtle AJ; Brock S; Cathomas R; Chakraborti P; Chowdhury S; Cook A; Elliott T; Gale J; Gibbs S; Graham JD; Hetherington J; Hughes R; Laing R; McKinna F; McLaren DB; O'Sullivan JM; Parikh O; Peedell C; Protheroe A; Robinson AJ; Srihari N; Srinivasan R; Staffurth J; Sundar S; Tolan S; Tsang D; Wagstaff J; Parmar MK;
    Lancet; 2016 Mar; 387(10024):1163-77. PubMed ID: 26719232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
    James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Anderson J; Popert RJ; Sanders K; Morgan RC; Stansfeld J; Dwyer J; Masters J; Parmar MK
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):577-81. PubMed ID: 18760574
    [No Abstract]   [Full Text] [Related]  

  • 4. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
    James ND; Sydes MR; Mason MD; Clarke NW; Anderson J; Dearnaley DP; Dwyer J; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann GN; Bertelli G; Birtle AJ; O'Sullivan JM; Protheroe A; Sheehan D; Srihari N; Parmar MK;
    Lancet Oncol; 2012 May; 13(5):549-58. PubMed ID: 22452894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
    Vale CL; Burdett S; Rydzewska LHM; Albiges L; Clarke NW; Fisher D; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Sweeney CJ; Sydes MR; Tombal B; Tierney JF;
    Lancet Oncol; 2016 Feb; 17(2):243-256. PubMed ID: 26718929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
    Mason MD; Clarke NW; James ND; Dearnaley DP; Spears MR; Ritchie AWS; Attard G; Cross W; Jones RJ; Parker CC; Russell JM; Thalmann GN; Schiavone F; Cassoly E; Matheson D; Millman R; Rentsch CA; Barber J; Gilson C; Ibrahim A; Logue J; Lydon A; Nikapota AD; O'Sullivan JM; Porfiri E; Protheroe A; Srihari NN; Tsang D; Wagstaff J; Wallace J; Walmsley C; Parmar MKB; Sydes MR;
    J Clin Oncol; 2017 May; 35(14):1530-1541. PubMed ID: 28300506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.
    Sydes MR; Parmar MK; James ND; Clarke NW; Dearnaley DP; Mason MD; Morgan RC; Sanders K; Royston P
    Trials; 2009 Jun; 10():39. PubMed ID: 19519885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
    James ND; Pirrie SJ; Pope AM; Barton D; Andronis L; Goranitis I; Collins S; Daunton A; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Hussain S; Russell M; Billingham LJ
    JAMA Oncol; 2016 Apr; 2(4):493-9. PubMed ID: 26794729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):11-3. PubMed ID: 27167844
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
    Kattan J; Bachour M; Farhat F; El Rassy E; Assi T; Ghosn M
    Invest New Drugs; 2016 Aug; 34(4):474-80. PubMed ID: 27159981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAMPEDE trial and patients with non-metastatic prostate cancer.
    Gandaglia G; Fossati N; Suardi N; Montorsi F; Briganti A
    Lancet; 2016 Jul; 388(10041):234-5. PubMed ID: 27479564
    [No Abstract]   [Full Text] [Related]  

  • 13. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.
    Sydes MR; Parmar MK; Mason MD; Clarke NW; Amos C; Anderson J; de Bono J; Dearnaley DP; Dwyer J; Green C; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann G; James ND
    Trials; 2012 Sep; 13():168. PubMed ID: 22978443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply.
    James ND; Sydes MR; Clarke NW; Mason MD; Parmar MK
    Lancet; 2016 Jul; 388(10041):235-6. PubMed ID: 27479566
    [No Abstract]   [Full Text] [Related]  

  • 15. Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.
    Pan Y; Jin H; Chen W; Yu Z; Ye T; Zheng Y; Weng Z; Wang F
    Int Urol Nephrol; 2014 Dec; 46(12):2319-26. PubMed ID: 25224665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
    Sternberg CN
    Eur Urol; 2016 Jun; 69(6):1155-6. PubMed ID: 27302137
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
    Taneja SS
    J Urol; 2016 Oct; 196(4):1124-5. PubMed ID: 27628795
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
    Zhang P; Wen F; Fu P; Yang Y; Li Q
    Tumori; 2017 Jul; 103(4):380-386. PubMed ID: 28009424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
    Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
    BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.